Proceedings · Session S-600 · filed November 17, 2026
Translational ScienceSession paper
FDA Clears Two AstraZeneca Biologics in Four Days
FDA approvals on Nov. 13 and Nov. 16, 2026 give AstraZeneca a perioperative bladder cancer regimen (EFS HR 0.51) and a weekly nanobody injection for myasthenia gravis.
By Rebecca Stone4 min read723 words
Summary
- FDA approved durvalumab plus EV for muscle-invasive bladder cancer on Nov. 13, 2026 after Priority Review.
- VOLGA interim: EFS HR 0.51 (P < .0001) and OS HR 0.58 (P = .0027); grade 3/4 AEs 64% vs 44%.
- FDA approved gefurulimab for AChR-positive generalized myasthenia gravis on Nov. 16, 2026.
- PREVAIL (260 patients, 20 countries): MG-ADL treatment difference –1.6 at week 26 (P < .0001).
- Regimen structure: 3 neoadjuvant EV+durvalumab cycles, then 9 adjuvant durvalumab cycles.
![<![CDATA[AstraZeneca Secures 2 FDA Approvals in Bladder Cancer, Myasthenia Gravis]]>](/media/97/97c736a8cd72f5f6.1280.webp)
The FDA approved two AstraZeneca biologics within four days, clearing a perioperative durvalumab regimen for muscle-invasive bladder cancer on Nov. 13, 2026 and a self-injected nanobody for generalized myasthenia gravis on Nov. 16, 2026. One is an oncology combination given around surgery; the other is a once-weekly rare disease therapy. Together they place sharply different demands on development, manufacturing and supply chains.
What does the durvalumab approval cover?
The FDA approved Imfinzi (durvalumab) plus enfortumab vedotin (EV) as neoadjuvant treatment, followed by durvalumab monotherapy after radical cystectomy, following Priority Review. The indication covers adults with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based chemotherapy. Roughly 16,000 patients will be treated for MIBC in the US in 2026, and as many as half cannot take cisplatin because of impaired renal function or comorbidities.
The regimen carries a defined dosing structure: three cycles of durvalumab and EV before surgery, then nine cycles of adjuvant durvalumab.
The phase 3 VOLGA trial supplied the evidence. At a planned interim analysis, the regimen reduced the risk of disease progression, recurrence, not undergoing surgery, or death by 49% against radical cystectomy with or without approved adjuvant treatment (event-free survival hazard ratio, 0.51; 95% CI, 0.38–0.67; P < .0001). It cut the risk of death by 42% (overall survival HR, 0.58; 95% CI, 0.40–0.83; P = .0027). Grade 3 and 4 adverse events from any cause hit 64% of combination-arm patients versus 44% in the comparator arm — a safety gap that clinicians and payers will weigh against the survival gains.
Jonathan Rosenberg, MD, chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center, said: "This approval brings the first perioperative immunotherapy regimen where enfortumab vedotin is administered only in the neoadjuvant setting to patients with muscle-invasive bladder cancer who are not candidates for cisplatin-based chemotherapy." He added that the VOLGA regimen "has the potential to become a new standard of care in this curative-intent setting."
What did the FDA approve for myasthenia gravis?
Alexion, AstraZeneca Rare Disease, gained approval of Klygefa (gefurulimab) for adults with generalized myasthenia gravis (gMG) who are antiacetylcholine receptor antibody-positive. It is the first and only dual-binding nanobody C5 inhibitor — a small antibody-like protein blocking the C5 complement protein — and patients self-administer it once weekly by subcutaneous autoinjector.
An estimated 98,500 people in the US have gMG; 81,000 of them are AChR-positive.
The phase 3 PREVAIL trial enrolled 260 patients across 20 countries. Gefurulimab improved the Myasthenia Gravis Activities of Daily Living total score from baseline at week 26 versus placebo (treatment difference, –1.6; 95% CI, –2.4 to –0.8; P < .0001), with improvement visible as early as week one. The most common treatment-emergent adverse events were injection site reactions (12%), back pain (8%) and vomiting (5%). The safety profile matched earlier trials of eculizumab and ravulizumab in gMG.
Kelly Gwathmey, MD, of Columbia University's Division of Neuromuscular Medicine, said: "In the PREVAIL Phase 3 trial, gefurulimab achieved both, delivering rapid and sustained functional improvements with a once-weekly subcutaneous self-administered injection."
Why do these approvals matter for R&D planning?
The durvalumab decision adds a second checkpoint inhibitor–EV regimen to perioperative MIBC care. In July, the FDA expanded pembrolizumab with EV in the same setting, previously reserved for patients unable to tolerate cisplatin.
The dosing split shapes manufacturing forecasts. VOLGA limits EV, an antibody-drug conjugate (an antibody linked to a cytotoxic payload), to three neoadjuvant cycles, while durvalumab runs across 12. A short, fixed ADC exposure changes how conjugation and high-containment capacity are forecast; the plain antibody supply must cover a longer adjuvant course.
Gefurulimab binds both C5 and serum albumin, which extends its half-life and enables weekly dosing. In October, Alexion's ravulizumab gained its fifth indication; it is delivered intravenously every eight weeks. The two formats pull portfolio capacity in opposite directions: a weekly home-use product stresses autoinjector assembly, combination-product quality systems and human-factors evidence, while an infusion product stresses infusion-center capacity and specialty distribution.
How AstraZeneca allocates ADC conjugation capacity against autoinjector fill-finish lines in 2027 will show whether its supply network can serve both launches at once.
via pharmtech.com (Source)
Filed under
- astrazeneca
- fda-approval
- durvalumab
- gefurulimab
- biologics
More from Rebecca Stone
Show full bio
Market editor covering regulation, policy and their impact on research and development at Hypothesis Wire.
274 articles
References
- FDA Approves Pimicotinib for TGCT on 56% Response Rate
- Cretostimogene Cuts Bladder Cancer Recurrence Risk 68% in Phase 3
- Cancer Cell publishes sac-TMT plus osimertinib translational data
- Neladalkib Wins Accelerated Approval: 49% ORR After Alectinib
- Merck Pulls Last-Resort Antibiotic Recarbrio From U.S. Market